OXB Confirms Manufacturing Partnership With Aura Biosciences for Phase 3 Cancer Therapy

COMPANY PROFILE
OXB
  • OXB has confirmed a manufacturing and supply partnership with Aura Biosciences to support late-stage development and manufacturing of belzupacap sarotalocan (bel-sar), an investigational therapy for ocular cancers.
  • OXB has initiated technical transfer at its US facilities in preparation for process performance qualification (PPQ) and potential commercial production.

OXB, a cell and gene therapy contract development and manufacturing organization (CDMO), has confirmed a manufacturing and supply partnership with Aura Biosciences to support the late-stage development of belzupacap sarotalocan (bel-sar), an investigational therapy for ocular cancers. The collaboration will support the program through Phase 3 development and prepare for potential future commercial supply.

The partnership will use OXB’s process and analytical development facility in Bedford, Massachusetts, and its FDA-approved commercial-scale viral vector manufacturing facility in Durham, North Carolina. The Durham site combines drug substance manufacturing with fill-and-finish capabilities. OXB has initiated technical transfer in preparation for process performance qualification and commercial production.

The work is intended to support Aura’s manufacturing readiness for late-stage clinical development, potential regulatory filings and commercialization. Bel-sar is a virus-like drug conjugate (VDC), marking OXB’s expansion into this manufacturing segment alongside its established viral vector capabilities.

OXB brings more than 30 years of experience in viral vector process development, analytical services and GMP manufacturing for clinical and commercial programs.

“The company’s experience in process characterization and PPQ will support the program as it advances through Phase 3 development.”

Dr. Sebastien Ribault, Chief Business Officer of OXB
EXCLUSIVE DOWNLOAD

Download the full CDMO Live Report for 112 pages of insights and best practices in external manufacturing.